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mice expressing the C-terminally truncated (1–120) form of 
human alpha-synuclein in dopaminergic neurons, a mouse 
model that recapitulates several biochemical, histopatho-
logical and behavioral characteristics of the early stage of 
PD.   Results:   Dimebon did not improve balance and coordi-
nation of aging transgenic animals or increase the level of 
striatal dopamine, nor did it prevent accumulation of alpha-
synuclein in cell bodies of dopaminergic neurons.   Conclu-
sion:   Our observations suggest that in the studied model of 
alpha-synucleinopathy dimebon has very limited effect on 
certain pathological alterations typical of PD and related dis-
eases.    Copyright © 2011 S. Karger AG, Basel 
 Introduction 
  Dimebon is an over-the-counter drug that has been 
used as a non-selective oral antihistamine from 1983 and 
until more selective agents became available. In addition 
to its major activity as an inhibitor of histamine H1 and 
H2 receptors   [1]  , dimebon has been reported to inhibit 
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 Abstract 
  Background:   R e c e n t  c l i n i c a l  s t u d i e s  h a v e  d e m o n s t r a t e d  
that dimebon, a drug originally designed and used as a non-
selective antihistamine, ameliorates symptoms and delays 
progress of mild to moderate forms of Alzheimer’s and Hun-
tington’s diseases. Although the mechanism of dimebon ac-
tion on pathological processes in degenerating brain is elu-
sive, results of studies carried out in cell cultures and animal 
models suggested that this drug might affect the process of 
pathological accumulation and aggregation of various pro-
teins involved in the pathogenesis of proteinopathies. How-
ever, the effect of this drug on the pathology caused by over-
expression and aggregation of alpha-synuclein, including 
Parkinson’s disease (PD), has not been assessed.   Objective:   
 To test if dimebon affected alpha-synuclein-induced pathol-
ogy using a transgenic animal model.   Methods:   We studied 
the effects of chronic dimebon treatment on transgenic 
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butyrylcholinesterase and acetylcholinesterase, voltage-
gated calcium channels, N-methyl-  D  -aspartatic acid, ad-
renergic receptors and serotonin receptors and mito-
chondrial permeability transition pore opening, as well 
as to stabilize glutamate-induced Ca  2+   signals and en-
hance hippocampal neurogenesis   [2–6]  . Consequently, it 
has been suggested that dimebon may be used as a neu-
roprotective drug slowing down the progression of dis-
eases characterized by gradual deprivation of cognitive 
functions.
    Indeed, dimebon demonstrated cognition and memo-
ry-enhancing properties in rats treated with the neuro-
toxin AF64A, a compound that selectively destroys cho-
linergic neurons, and it protected cerebellar neurons in 
cell culture against beta-amyloid fragment-caused neuro-
toxicity  [7] . In clinical trials dimebon improved cognition 
and memory of Alzheimer’s disease   [8]   and Huntington’s 
disease   [9]   patients. The pathogenesis of these two etio-
logically and clinically diverse neurodegenerative disor-
ders shares a common feature, namely accumulation and 
deposition of aggregation-prone proteins (beta-amyloid 
and huntingtin, respectively) and therefore, they belong 
to a class of diseases known as proteinopathies  [10] , which 
also include Parkinson’s disease (PD). A suggestion that 
dimebon may interfere with the process of protein aggre-
gation and deposition instigated studies of the effect of 
this drug in various models of proteinopathies. It has been 
demonstrated that dimebon is capable of inhibiting the 
formation of TDP-43 inclusions in cellular models   [11]  
and the formation/clearance of pathological deposits in a 
mouse model of gamma-synucleinopathy   [12] .
    One of the most prominent features of PD is aggrega-
tion of alpha-synuclein with formation of toxic interme-
diates and characteristic cytoplasmic deposits of final ag-
gregation products   [13]  . However, the effect of dimebon 
on alpha-synuclein aggregation in models of this neuro-
degenerative disorder or on disease progression in PD pa-
tients has not been assessed. The aim of the present study 
was to check whether dimebon is able to ameliorate the 
pathology caused by accumulation of alpha-synuclein in 
vivo.
    Transgenic mice expressing mutated forms of hu-
man alpha-synuclein, which cause neuronal dysfunction 
through a toxic gain-of-function mechanism, are the 
most adequate model systems for such study. It is beyond 
doubt that successful neuroprotective therapies would be 
most effective when used at an early clinical or even pre-
clinical stage of the disease when it is still possible to slow 
down or reverse its development. Thus, it seemed reason-
able to assess the effect of dimebon in a mouse model 
replicating early stages of PD pathology. Mice expressing 
the truncated (lacking the C-terminal 20 amino acids) 
form of human alpha-synuclein under control of tyrosine 
hydroxylase (TH) promoter on the endogenous alpha-
synuclein null background, further referred to as aSyn 
(1–120) TG, recapitulate features of early-stage PD. Adult 
mice show no marked loss of dopaminergic neurons and 
only minor defects in the nigrostriatal system   [14] .  The 
late-onset pathology includes rare human alpha-synucle-
in-positive neuronal inclusions, reduction in striatal do-
pamine content associated with decreased locomotion 
and progressive reduction of striatal dopamine release as-
sociated with SNARE protein redistribution and synaptic 
alpha-synuclein accumulation   [15]  . However, these ani-
mals do not develop severe motor deficit characteristic 
for advanced stages of PD   [13]  . Olfactory impairment is 
observed in 70–95% of patients with PD and precedes the 
severe motor symptoms by up to 4 years   [16–18]  . In aSyn 
(1–120) TG mice the highest levels of exogenous trans-
gene expression and accumulation were detected in the 
olfactory bulb (OB) dopaminergic neurons  [14] . The aSyn 
(1–120) TG mice represent a model mirroring the earliest 
alterations in the dopaminergic systems that precede sig-
nificant neuronal loss in PD. Here, we use this model to 
study the effects of chronic dimebon treatment on bio-
chemical and histological markers of pathology induced 
by expression of mutated human alpha-synuclein.
  Animals  and  Methods 
 Animals 
 The transgenic mouse line aSyn (1–120) TG was created on the 
alpha-synuclein null background  [18]  as described previously  [14, 
15]  . Only male mice were used in this study. Experimental mice 
were housed one per cage with a normal light/dark cycle and ad 
libitum access to food and water. All animal experiments were 
carried out in accordance with the UK Animals (Scientific Proce-
dures) Act, 1986. The minimal required number of animals was 
used and all efforts were made to minimize animal suffering.
  Dimebon  Administration 
 Dimebon (3,6-dimethyl-9-(2-methyl-pyridyl-5)-ethyl-1,2,3,4-
tetrahydro-     -carboline dihydrochloride) was obtained from 
OJSC Organika (Novokuznetsk, Russia). A cohort of aSyn (1–120) 
TG male mice received dimebon with the drinking water (10     g/
ml solution that was changed 3 times a week) from the age of 3 
months. Control littermate animals received drinking water 
without dimebon. At the age of 14 months mice were behavior-
ally tested and tissues were collected for further analysis.
  Behavioral  Tests 
  Home-Like Cage Activity.  Spontaneous locomotor activity was 
assessed in the home-like cage equipped with a system of infrared   Shelkovnikova et al.  Neurodegenerative Dis 2011;8:430–437  432
beams to monitor horizontal movements. Animals were moni-
tored for 24 h with a normal light/dark cycle and ad libitum access 
to food and water. Exploratory activity in the novel environment 
was analyzed for 2 h after placing mice in the home-like cage for 
the first time. Data (number of beam breaks) were collected at 15-
min intervals. 
   Rotarod Test.   Animals were introduced to the rotarod (UGO 
Basil 7560, Italy) for 5 min and tested using an accelerating (from 
4 to 40 rpm over 300 s) mode later on the same day. Each animal 
was tested 3 times with a 30-min break between tests. The mean 
of latency to fall for these three trials was included in final statis-
tics. Results were expressed as mean  8  SEM for each experimen-
tal group.
   Inverted Grid Test.   Balance and coordination were assessed as 
the ability of animals to stay on the inverted grid. Mice were 
placed on a 30 ! 30 cm square mesh consisting of 5-mm squares 
of 0.5-mm diameter wire. The grid was slowly rotated to inverted 
position and held 30 cm above the surface of a thick layer of bed-
ding material. The latency to fall (in seconds) was noted. The 
maximum test time was 60 s. The best time from three attempts 
was included in the statistics.
  Immunohistochemistry 
  For the quantification of dopaminergic neurons in the sub-
stantia nigra pars compacta (SNpc) and ventral tegmental area, 
brains of control and experimental animals were simultaneously 
collected, processed, embedded and stained with antibody against 
TH as described previously   [20, 21]  . Alexa Fluor-conjugated goat 
anti-rabbit and anti-mouse antibodies (Invitrogen) were used as 
secondary antibodies in double-immunofluorescence experi-
ments.
  Neuronal  Cell  Counts 
  Dopaminergic neurons in the SNpc and ventral tegmental 
area of experimental and control mice were stereologically count-
ed using fractionator method and the Axiovision imaging pro-
gram (Carl Zeiss Vision) as described in our previous publications 
  [20, 21] . 
  A n t i b o d i e s  
  Mouse monoclonal antibody against TH (clone TH-2, Sigma) 
was used for staining of histological sections in 1:    1,000  dilution. 
Mouse monoclonal antibody Syn-1 (Transduction Laboratories) 
was used in 1:     1,500 dilution for detection of alpha-synuclein on 
immunoblots and in 1:     100 dilution for double-immunofluores-
cence analysis together with rabbit polyclonal antibody against 
TH (H-196, Santa Cruz Biotechnology) diluted 1:    100.
    High-Pressure Liquid Chromatography Analysis 
  Monoamines were extracted by homogenization of dissected 
mouse dorsal striata in 0.06   M   HClO 4  . Concentrations of striatal 
dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) were 
measured by high-pressure liquid chromatography (HPLC) with 
electrochemical detection using a 4.6   !   150 mm Microsorb C18 
reverse-phase column (Varian) and Decade II ECD with a Glassy 
carbon working electrode (Antec Leyden) set at +0.7 V with re-
spect to a Ag/AgCl reference electrode. The mobile phase con-
sisted of 12% methanol (v/v), 0.1   M   monosodium phosphate, 2.4 
m  M   1-octane sulphonic acid, 0.68 m  M   EDTA, pH 3.1.
  I m m u n o b l o t t i n g  
  Olfactory bulbs were dissected and homogenized directly in 
SDS-PAGE loading buffer followed by incubation for 10 min at 
100    °    C. Protein concentration was measured, and equal amounts 
of total protein were run on 14% SDS-PAGE and transferred to 
PVDF membrane using iBlot technology according to manufac-
turer’s (Invitrogen) instructions. Membrane blocking, incubation 
with antibodies, washes and enhanced chemiluminescence detec-
tion were carried out as described previously   [20, 21] .
  RNA  Expression  Analysis 
 Total RNA extraction, first-strand cDNA synthesis and quan-
titative PCR on a StepOne Real-Time PCR System (Applied Bio-
systems) were performed as described previously   [22] .  Primers 
5   -GAATCCTGGAAGACATGCCT-3    and 5   -AGGCTTCAG-
GCTCATAGTCT-3     were used for amplification of alpha-synu-
clein cDNA. For amplification of GAPDH mRNA (normalization 
standard) primers 5   -CACTGAGCATCTCCCTCACA-3    and 5   -
GTGGGTGCAGCGAACTTTAT-3     were used. Fold change was 
determined by 2  –       CT   method   [23]   using StepOne v2.0 software.
  Statistical  Analysis 
 All    calculations were performed using STATISTICA 6.0 soft-
ware. Non-parametric Kruskal-Wallis one-way ANOVA on ranks 
and Mann-Whitney U test were used to assess differences be-
tween experimental groups.
  R e s u l t s  
  Effect of Chronic Dimebon Treatment on Mouse 
Locomotion, Exploratory Activity, Balance and 
Coordination 
  Analysis of dimebon-treated and control mice loco-
motion in a home-like cage during a 24-hour period re-
vealed no statistically significant difference (p = 0.662) 
between the groups (  fig. 1  A). This indicates that chronic 
dimebon treatment does not affect spontaneous locomo-
tor activity of aSyn (1–120) TG mice. However, dimebon-
treated transgenic mice were significantly (p = 0.019) 
more active than control transgenic mice in a novel non-
anxiogenic environment during the first 15 min of ha-
bituation, when their activity was similar to activity of 
wild-type mice (  fig. 1  B).
    Balance and coordination of transgenic mice that did 
or did not receive dimebon and age-matched wild-type 
animals were assessed in inverted grid and accelerating 
rotarod tests (  fig. 1  C, D). No difference in the ability to 
stay on the inverted grid was observed between the three 
groups (p   1   0.05). Although 14-month-old aSyn (1–120) 
TG mice noticeably underperformed in the rotarod test 
compared to wild-type animals of the same age (p = 
0.030), chronic administration of dimebon did not im-
prove their performance (p = 0.806).  Dimebon Does Not Ameliorate
Alpha-Synuclein Pathology 
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    Dopaminergic Neurons in the SNpc and Dopamine 
Content in the Dorsal Striatum of Dimebon-Treated 
Alpha-Synuclein Transgenic Animals 
  It has previously been reported that expression of 
truncated human alpha-synuclein in dopaminergic neu-
rons results in the development of pathological changes 
in the SNpc of aSyn (1–120) TG mice by the age of 12–14 
months   [14]  . These changes include shrunken perikarya, 
beaded or dystrophic processes, inclusions and micro-
gliosis, and may lead to progressive dysfunction of do-
pamin ergi c n eur o ns. Th er ef o r e, w e assessed eff ects o f 
chronic dimebon administration on the number of dopa-
minergic neurons in the SNpc and dopamine content in 
the dorsal striatum of aSyn (1–120) TG mice. Stereologi-
cal counting of TH-positive neurons showed that both 
dimebon-treated and non-treated transgenic mice have 
the same number of dopaminergic neurons in the SNpc 
(  fig. 2  A) as wild-type mice. This is consistent with the 
earlier observation that transgene expression does not 
cause   detectable   loss   of    TH-positive    neurons    in    the    
SNpc   of   aSyn   (1–120) TG mice   [24]   and demonstrates 
that dimebon has no effect on the survival of SNpc or 
ventral tegmental area (online supplementary fig. 1, see 
www.karger.com/doi/10.1159/000324989) dopaminergic 
neurons in adult animals. In contrast to unchanged num-
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  Fig. 1.  Locomotor activity, balance and coordination of 14-month-
old dimebon-treated and control mice.   A   Spontaneous locomo-
tion of mice in the home-like cage measured as the number of 
beam breaks per 1-hour interval over a period of 24 h. The dark 
phase of the light cycle is shaded. Graphs show results (means   8  
SEM) for 8 dimebon-treated and 7 naïve aSyn (1–120) TG mice. 
Statistical analysis revealed no significant difference between two 
groups.   B   Locomotor activity of mice in novel non-anxiogenic 
environment recorded during the first 120 min in a home-like 
cage. Graphs show means   8   SEM of the number of beam breaks 
per 15-min interval for each group of animals. Statistically sig-
nificant differences between activity of dimebon-treated and na-
ïve aSyn (1–120) TG mice (  *  p   !   0.05) or naïve aSyn (1–120) TG 
and wild-type (WT) mice (  #  p   !   0.05) are shown. Bar charts show 
means   8   SEM of latency to fall from the inverted grid (  C  ) or ac-
celerating rotarod ( D ). aSyn (1–120) TG mice perform significant-
ly worse (  #  p   !   0.05) than wild type mice in accelerating rotarod 
but not inverted grid test and dimebon does not affect their per-
formance in both tests.   Shelkovnikova et al.  Neurodegenerative Dis 2011;8:430–437  434
metabolites is significantly reduced in the dorsal stria-
tum of adult and aging aSyn (1–120) TG mice   [14] ,  which 
reflects the compromised function of the dopaminergic 
system in these mice   [15]  . Our HPLC analysis demon-
strated the same dopamine and DOPAC content in the 
dorsal striatum of dimebon-treated and non-treated 
transgenic mice (   fig. 2  B, C ) , suggesting that dimebon 
does not improve dopaminergic neuron function in this 
animal model. 
    Dimebon Does Not Alter Transgene Expression, 
Accumulation or Intracellular Localization of
Alpha-Synuclein in Dopaminergic Neurons of the 
Olfactory Bulb 
  In aSyn (1–120) TG mice, the highest level of exoge-
nous alpha-synuclein expression driven by the TH pro-
moter was observed in the OB. To assess whether dime-
bon might influence the expression of transgene in neu-
rons we studied the levels of human alpha-synuclein 
mRNA by quantitative RT-PCR and protein by immu-
noblotting in the OB of dimebon-treated and control 
aSyn (1–120) TG mice. For these experiments OBs of 6 
dimebon-treated transgenic mice were combined in one 
group (D1) and OBs of another 4 similarly treated ani-
mals in another group (D2). Similarly, OBs of 4 and 5 
non-treated transgenic mice were combined in groups C1 
and C2. Total RNA and total proteins form each group of 
combined tissues were extracted and analyzed. The same 
level of human alpha-synuclein mRNA was detected in 
all four groups (  fig. 3  A). On immunoblots, the intensity 
of bands corresponding to the 12-kDa truncated form of 
human alpha-synuclein protein was also very similar in 
four samples (  fig. 3  B). These results clearly demonstrate 
that dimebon does not affect transgene expression from 
the TH promoter or accumulation of exogenous alpha-
synuclein in dopaminergic neurons of the OB. 
    In contrast to predominantly presynaptic compart-
mentalization of endogenous full-length alpha-synuclein 
and its exclusion from the perikaryon of dopaminergic 
neurons in the glomerular layer of OB, ectopic accumula-
tion of truncated human alpha-synuclein was observed 
in the cell bodies of these neurons (  fig. 3  C). However, si-
multaneous immunofluorescent staining of histological 
sections through the OB of dimebon-treated and control 
transgenic mice revealed no changes in either localiza-
tion or the amount of alpha-synuclein accumulated in the 
cell bodies (  fig. 3  D).
  Discussion 
  A disease-modifying effect of dimebon on the mild to 
moderate form of Alzheimer’s disease and Huntington’s 
disease has been demonstrated in phase II clinical trials 
  [8]  . Together with the recently shown ability of this drug 
to improve behavioral and histopathological impair-
ments caused by pan-neuronal overexpression of gam-
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  Fig. 2.   The number of dopaminergic neurons in the substantia 
nigra and the content of monoamines in the dorsal striatum of 
14-month-old dimebon-treated and control transgenic mice.
  A  Bar chart shows means  8  SEM of total numbers of TH-positive 
neurons in the SNpc (per hemisphere) of dimebon-treated and 
control aSyn (1–120) TG mice. No statistically significant differ-
ence between groups was found. Tissue content of dopamine (DA, 
  B ) and DOPAC (  C ) in the dorsal striatum of dimebon-treated and 
control aSyn (1–120) TG mice measured by HPLC with electro-
chemical detection and expressed as picomoles per milligram of 
tissue. Means   8   SEM are shown. Statistical analysis revealed no 
significant difference between the groups.   Dimebon Does Not Ameliorate
Alpha-Synuclein Pathology 
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dimebon might be efficient in the treatment of various 
types of proteinopathies, including PD. Therefore, the 
main aim of this study was to evaluate the effects of dime-
bon in a mouse model recapitulating several characteris-
tics of early-stage PD because results of clinical trials sug-
gested that dimebon might protect against early rather 
than advanced forms of neurodegeneration. Experimen-
tal animals had constant access to drinking water con-
taining 10      g/ml of dimebon that was changed every 
60 h. Because of the stability of this compound in solu-
tions  [25–27]  and the same rate of consumption for water 
and dimebon solution (average daily water consumption 
for mice in the control group was 5.2 ml and average dai-
ly dimebon solution consumption for mice in the experi-
mental group was 5.4 ml) this protocol permitted to 
achieve a cumulative daily dose of   54    g/30–35 g mouse 
or     1.5 mg/kg. This dose is close to the dose (1 mg/kg) 
used in the phase II clinical trials of dimebon for patients 
with Alzheimer’s disease   [8]  . Moreover, recent studies 
have demonstrated that after oral administration of a sin-
gle dose, dimebon levels in the plasma and in the brain of 
rodents are stable for at least 6 h   [28]   and therefore, our 
p r o t o c o l  o f  d r u g  a d m i n i s t r a t i o n  w i t h  d r i n k i n g  w a t e r  
supplied ad libitum assures uninterrupted exposure of 
the experimental animal brain to dimebon.
    Mice of the aSyn (1–120) TG line expressing a trun-
cated form of human alpha-synuclein in catecholaminer-
gic neurons have previously been shown to develop an 
age-dependent reduction in exploratory activity in a nov-
el environment   [14]  . Here we confirmed this effect on a 
separate cohort of 14-month-old aSyn (1–120) TG mice 
and over a longer period of adaptation to a novel environ-
ment ( 120 min in contrast to 30 min in the previous 
study), and furthermore revealed that performance of 
these transgenic mice in the accelerated rotarod test is 
also markedly compromised when compared to the per-
formance of age-matched wild-type animals. However, 
aging aSyn (1–120) TG mice performed very similarly to 
wild-type animals in the inverted grid test, suggesting 
that expression of the truncated form of human alpha-
synuclein in dopaminergic neurons causes very selective 


















































  Fig. 3.   Expression and accumulation of truncated human alpha-
synuclein in the OB of 14-month-old transgenic mice.   A   Quanti-
tative RT-PCR analysis of human alpha-synuclein mRNA expres-
sion in the OB of dimebon-treated (D1 and D2) and control (C1 
and C2) groups of aSyn (1–120) TG mice. The bar chart shows the 
fold of alpha-synuclein mRNA level (mean   8   SEM) normalised 
to the mean level in the D1 group.   B   Immunoblot detection of 12-
kDa truncated human alpha-synuclein in protein samples ex-
tracted from OBs of the same animal groups as in  A . Total protein 
extracts (10      g per lane) were separated by SDS-PAGE, trans-
ferred to PVDF membrane and probed with antibody against al-
pha-synuclein followed by enhanced chemiluminescence detec-
tion.   C ,   D   Immunofluorescent staining of histological sections 
through the glomerular layer of the OB of control (panels   C–C’’ ) 
and dimebon-treated (panels   D–D’’  ) aSyn (1–120) TG mice with 
antibodies against TH (  C ,   D  ) and alpha-synuclein (  C’ ,   D’ ).  Scale 
bar = 20      m for all panels.       Shelkovnikova et al.  Neurodegenerative Dis 2011;8:430–437  436
80% reduction of striatal dopamine is required for the 
development of motor symptoms, whereas aSyn (1–120) 
TG mice display only     30% reduction   [14] ,  suggesting 
that their compromised rotarod performance could not 
be explained simply by dopamine deficiency but probably 
involves other functional changes in dopaminergic neu-
rons or their synapses caused by expression of truncated 
human alpha-synuclein   [15]  . Thus, two behavioral pa-
rameters that appeared to be compromised in aSyn (1–
120) TG mice could be used for assessing the effect of 
dimebon on alpha-synuclein-induced pathology. 
  Transgenic mice chronically treated with dimebon for 
11 months from the age of 3 months showed no improve-
ment in the accelerated rotarod test compared to untreat-
ed animals of the same genotype. This correlated with the 
lack of the effect of dimebon on decreased levels of dopa-
mine and DOPAC in the striatum of aSyn (1–120) TG 
mice. 
    The general activity of aging aSyn (1–120) TG mice in 
the home-like cage over a 24-hour period was not affect-
ed by dimebon. However, immediately after placing in a 
novel environment, dimebon-treated animals were sig-
nificantly more active than untreated transgenic ani-
mals, suggesting that dimebon intensifies exploratory ac-
tivity, which is attenuated in 14-month-old aSyn (1–120) 
TG mice. As exploratory behavior depends on the coor-
dinated function of many brain networks rather than 
solely the dopaminergic system, this effect might reflect 
a general improvement of aging brain function by dime-
bon as suggested in previous studies   [6–8, 29] .
    Another prominent feature of the aSyn (1–120) TG 
model is the ectopic accumulation of transgenically ex-
pressed truncated human alpha-synuclein in cell bodies 
of dopaminergic neurons. This was most obvious in neu-
rons of the glomerular layer of OB and therefore these 
cells seemed an appropriate system for assessing the ef-
fect of dimebon treatment on alpha-synuclein accumula-
tion and intraneuronal localization. However, neither ex-
pression analysis nor the comparison of histological sec-
tions through the OB revealed differences in the tissue 
level or in the pattern of human alpha-synuclein immu-
nostaining in TH-positive neurons of dimebon-treated 
and untreated aSyn (1–120) TG mice. We also did not ob-
serve any effect of dimebon on micro- or astrogliosis in 
the OB or other neural tissues of these mice.
  In conclusion, we demonstrated a very limited effect of 
chronic dimebon treatment on the biochemical, histolog-
ical and behavioral alterations caused by expression of 
truncated human alpha-synuclein in dopaminergic neu-
rons of transgenic mice. Although these negative results 
question the value of dimebon as a potential treatment for 
PD and other alpha-synucleinopathies, it should be noted 
that aSyn (1–120) TG mice recapitulate only some chang-
es typical of the early stages of these diseases and it is pos-
sible that this drug might affect other manifestations, for 
example, those associated with late disease stages. Further 
studies are required to reveal whether dopaminergic neu-
rons are less sensitive to this drug than other previously 
studied types of neurons or whether dimebon does not 
affect pathways associated with alpha-synuclein toxicity 
in any other types of cells and at any stage of pathology.
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